Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells

Although imatinib is effective in chronic myeloid leukemia treatment, imatinib resistance due to the T315I mutation and/or other mutations is a challenge to be overcome. However, how DNA mutation occurs, particularly the T315I mutation, remains unclear. In the current study, the mutagenesis of BCR-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Yan, Gao, Xiaotong, Zhao, Yingxin, Wei, Mengying, Xu, Lingmin, Yang, Guodong, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779997/
https://www.ncbi.nlm.nih.gov/pubmed/29152650
http://dx.doi.org/10.3892/mmr.2017.7835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779997/
https://www.ncbi.nlm.nih.gov/pubmed/29152650
http://dx.doi.org/10.3892/mmr.2017.7835

Ejemplares similares